C4 Therapeutics Inc
Company Profile
Business description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Contact
490 Arsenal Way
Suite 120
WatertownMA02472
USAT: +1 617 231-0700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
104
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
stocks
Avoid this overvalued ASX lithium producer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 24,994.83 | 254.47 | 1.03% |
| Dow JONES (US) | 51,922.09 | 73.19 | 0.14% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,317.09 | 159.54 | -0.63% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,351.95 | 6.27 | -0.09% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |